# CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria

> **NCT03477422** · PHASE3 · COMPLETED · sponsor: **Venus Remedies Limited** · enrollment: 230 (actual)

## Conditions studied

- Urinary Tract Infection Complicated
- Acute Pyelonephritis

## Interventions

- **DRUG:** CSE-1034 (Ceftriaxone + Sulbactam + EDTA)
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT03477422
- **Lead sponsor:** Venus Remedies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-11
- **Primary completion:** 2017-05-08
- **Final completion:** 2017-05-08
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2019-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03477422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03477422, "CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03477422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*